ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1148

The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA

Arjen Leek1, Jordi Anton2, Tadej Avcin3, Fabrizio De Benedetti4, Victor Boom1, Claudia Bracaglia5, Paul Brogan6, Tamas Constantin7, Alessandro Consolaro8, Pavla Dolezalova9, Despina Eleftheriou10, Helen Foster11, Claas Hinze12, Isabelle Koné-Paut13, Kirsten Minden14, Francesca Minoia15, Pierre Quartier16, Angelo Ravelli8, Nicolino Ruperto17, Joost Swart18, Yosef Uziel19, Helmut Wittkowski20, Carine Wouters21, Mojca Zajc Avramovitz22, Nico Wulffraat18 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Sant Joan de Déu Hospital, Madrid, Spain, 3Ljubljana University Medical Centre, Ljubljana, Slovenia, 4Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 5Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 6UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 7Semmelweiss University Hospital, Budapest, Hungary, 8Università degli Studi di Genova, Genoa, Italy, 9University Hospital Prague, Prague, Czech Republic, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, 11Newcastle University, Newcastle upon Tyne, United Kingdom, 12University Hospital M�nster, M�nster, Germany, 13Necker Hospital, Paris, France, 14Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 15Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 16Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 17Istituto Giannina Gaslini, Genova, Italy, 18IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, 19Meir Medical Center, Kfar Saba, Israel, 20University Hospital Muenster, Muenster, Germany, 21University Hospital Leuven, Leuven, Belgium, 22University Hospital Ljubljana, Ljubljana, Slovenia

Meeting: ACR Convergence 2020

Keywords: Clinical practice guidelines, Juvenile idiopathic arthritis, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability of interleukin-1 (IL-1) and IL-6 inhibitor treatment, morbidity has significantly reduced and the (long term) outcome for sJIA patients has improved over the last decade. However, differences in access to care and differences in treatment strategies between countries in and outside of Europe remain a concern.

The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) consortium aimed to develop best practices for paediatric rheumatic diseases in order to decrease differences in care between European countries. Here, we present the final results of the literature review and a series of consensus meetings on defining overarching, diagnostic and therapeutic recommendations for diagnosis and treatment of systemic JIA.

Methods: The SHARE methodology concerning consensus-based principles and guidelines has been previously published, including the use of the EULAR standardized operating procedure for developing best practice recommendations(1). As per these guidelines, a methodologist provided supervision during the process and consensus meetings.

A systematic literature search of the Medline, Embase and Cochrane databases was performed in June 2013 and this was updated in November 2019. Results were used to develop and support recommendations on diagnosis, treatment and complications of systemic JIA. These recommendations were pre-tested in an online survey to a task-force of expert paediatric rheumatologists to assess potential agreement and enable rewording. The participating experts convened in 3 consensus meetings (Genua 2014, Barcelona 2015 and Utrecht 2020) to develop the best practices. Making use of the Nominal Group Technique, recommendations were proposed, discussed and voted on. Recommendations that reached ≥80% were accepted in this guideline.

Results: The 2-step systematic literature review finally included 98 papers on sJIA. Quality and grade of evidence was assessed and a categorized overview was used as backbone and reference during the consensus meeting. In total, 15 recommendations were developed and accepted in the final consensus meeting: 4 overarching principles, 3 diagnostic recommendations and 8 recommendations on treatment of sJIA and its complications. Recommendations are presented with accompanying level of evidence (LoE), strength of recommendation (SoR) and percentage of agreement (PoA). In addition, adherence to the 2018 EULAR Treat-to-Target principles on JIA was confirmed by the expert panel.

Conclusion: These SHARE best practices on sJIA are based on the best available evidence and expert opinion, and provide recommendations for the diagnosis and treatment of patients with sJIA, aiming to improve the outcome for all sJIA patients in Europe and beyond.


Disclosure: A. Leek, None; J. Anton, Sobi, 1, 2, 3, Novartis, 1, 2, 3, GSK, 1, 2, 3, Pfizer, 1, 2, BMS, 1, Chemocentryx,, 1, Lilly, 1, Novimmune, 1, Sanofi, 1, Roche, 1; T. Avcin, AbbVie, 5, 8, Alexion, 5, Octapharma, 5, 8, Takeda, 5, 8; F. De Benedetti, Novartis, 2, 8, Novimmune, 2, 9, Sobi, 2, 8, 9, Roche, 2, 8, Pfizer, 2, Sanofi, 2, AbbVie, 8; V. Boom, None; C. Bracaglia, SOBI, 8; P. Brogan, Sobi, Roche, Novartis, 2, 5; T. Constantin, None; A. Consolaro, None; P. Dolezalova, SOBI, 5; D. Eleftheriou, None; H. Foster, Sanofi-Genzyme, 2; C. Hinze, Novartis, 5; I. Koné-Paut, None; K. Minden, Sanofi, 1, gsk, 1, Roche, 1, Abbvie, 1, Biermann, 8, Medac, 8; F. Minoia, None; P. Quartier, AbbVie, 1, Bristol-Myers Squibb, 1, Chugai-Roche, 1, Lilly, 1, Novartis, 1, Novimmune, 1, Sanofi, 1, Sobi, 1; A. Ravelli, AbbVie, BMS, Pfizer, Hoffman LaRoche, Novartis, Centocor, "Francesco Angelini" and Reckitt Benckiser., 1, 2; N. Ruperto, Ablynx, 5, 8, Astrazeneca-Medimmune, 5, 8, Biogen, 5, 8, Boehringer, 5, 8, Bristol Myers Squibb, 2, 5, 8, 9, Eli Lilly, 2, 5, 8, 9, EMD Serono, 5, 8, GlaxoSmithKline, 2, 5, 8, 9, F Hoffmann-La Roche, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Merck, 5, 8, Novartis, 2, 5, 8, 9, Pfizer, 2, 5, 8, 9, R-Pharma, 5, 8, Sanofi, 5, 8, Servier, 5, 8, Sinergie, 5, 8, Sobi, 2, 5, 8, 9, AbbVie, 5, 8, Takeda, 5, 8; J. Swart, SOBI, 8; Y. Uziel, Pfizer, 8; H. Wittkowski, Novartis, 8; C. Wouters, Novartis, 2; M. Zajc Avramovitz, None; N. Wulffraat, SOBI, 2; S. Vastert, Sobi, 1, 2, Novartis, 1.

To cite this abstract in AMA style:

Leek A, Anton J, Avcin T, De Benedetti F, Boom V, Bracaglia C, Brogan P, Constantin T, Consolaro A, Dolezalova P, Eleftheriou D, Foster H, Hinze C, Koné-Paut I, Minden K, Minoia F, Quartier P, Ravelli A, Ruperto N, Swart J, Uziel Y, Wittkowski H, Wouters C, Zajc Avramovitz M, Wulffraat N, Vastert S. The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-share-recommendations-on-diagnosis-and-treatment-of-systemic-jia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-share-recommendations-on-diagnosis-and-treatment-of-systemic-jia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology